Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Gilead Sciences : Kevin Young CBE, Gilead's Chief Operating Officer, to Retire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 06:02pm CET

By a News Reporter-Staff News Editor at Pharma Business Week -- Gilead Sciences, Inc. (Nasdaq: GILD) announced that Kevin Young CBE, Chief Operating Officer, plans to retire, effective early 2018. Mr. Young will remain with Gilead through the first quarter of next year and in an advisory capacity thereafter (see also Pharmaceutical Companies).

Mr. Young joined Gilead in 2004 to lead the company's worldwide commercial operations. He oversaw the introduction of multiple new products, including the first single tablet regimens for HIV and the first oral direct acting antiviral regimens for chronic hepatitis C. In 2014, Mr. Young retired from his full-time role and served as a senior advisor to Gilead until 2016, when he returned to assume the role of Chief Operating Officer. Prior to Gilead, he spent more than 20 years in the biopharmaceutical industry, first with ICI Pharmaceuticals and subsequently with Amgen. Mr. Young has undergraduate and graduate degrees in Sports Science and Exercise Physiology from Liverpool and Nottingham, England. In 2011, he was appointed a Commander of The British Empire, one of Great Britain's highest civilian honors, in recognition of his "services to the healthcare and pharmaceutical industries."

"Since Kevin joined Gilead in 2004, he has worked tirelessly to build Gilead's commercial success across numerous therapeutic areas and geographies," said John Martin, PhD, Executive Chairman. "Together with the Board of Directors, I am grateful that he came out of semi-retirement in May 2016 to strengthen Gilead and help establish the strategy and execute on plans for our next phase of growth in cell therapy."

"Kevin has had an impact on Gilead - and by extension on the field of medicine and the lives of patients - that is seldom seen," said John Milligan, PhD, President and Chief Executive Officer. "Those who have had the opportunity to work alongside Kevin know that he possesses both a deep commitment to his work and unparalleled leadership abilities. I am delighted that he will be helping us manage through a period of change over the next several months and I am deeply grateful to Kevin for his contributions to Gilead and to the lives of millions of people around the world." About Gilead Sciences Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

Keywords for this news article include: Pharmaceutical Companies, Biopharmaceuticals, Drugs and Therapies, Gilead Sciences Inc..

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
02/15GILEAD SCIENCES : New Data from Gilead Sciences Illuminate Findings in Antiretro..
AQ
02/15GILEAD SCIENCES : U.S. Food and Drug Administration Approves Gilead's Biktarvy® ..
AQ
02/15GILEAD SCIENCES : to Present at the RBC Capital Markets 2018 Global Healthcare C..
AQ
02/15GILEAD SCIENCES : Today’s Research Reports on Trending Tickers: Gilead Sciences ..
AC
02/12GILEAD SCIENCES : to Present at the RBC Capital Markets 2018 Global Healthcare C..
AQ
02/12PFIZER : ViiV Healthcare files patent infringement litigation against Gilead Sci..
AQ
02/10Gilead`s Biktarvy wins megablockbuster HIV nod, and rival GlaxoSmithKline str..
AQ
02/09GILEAD SCIENCES : U.S. Food and Drug Administration Approves Gileads Biktarvy
AQ
02/09GILEAD SCIENCES : Glaxo sues US firm for allegedly infringing on HIV drug patent
AQ
02/08GILEAD SCIENCES : to Present at the RBC Capital Markets 2018 Global Healthcare C..
BU
More news
News from SeekingAlpha
02/20BIOTECHS : Still Well Placed For More Gains 
02/20FDA tentatively OKs Mylan's HIV combo pill 
02/20Biotech Forum Daily Digest For February 20th 
02/20WALL STREET BREAKFAST : Albertsons Scoops Up Rest Of Rite Aid 
02/19Healthcare In Transition 
Financials ($)
Sales 2018 21 270 M
EBIT 2018 11 296 M
Net income 2018 6 975 M
Debt 2018 16 887 M
Yield 2018 2,79%
P/E ratio 2018 15,40
P/E ratio 2019 14,51
EV / Sales 2018 5,76x
EV / Sales 2019 5,67x
Capitalization 106 B
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 88,8 $
Spread / Average Target 9,7%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES14.21%105 702
VERTEX PHARMACEUTICALS4.94%40 647
REGENERON PHARMACEUTICALS-12.04%35 686
BIOVERATIV INC91.99%11 211
GENMAB4.28%10 637
BLUEBIRD BIO INC16.37%10 460